Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN
Biohaven Pharmaceutical Holding Company Ltd
Accounts Payable
Biohaven Pharmaceutical Holding Company Ltd
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN
|
Accounts Payable
$15.6m
|
CAGR 3-Years
77%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$31.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$622m
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$351.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
34%
|
CAGR 10-Years
22%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$671.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
23%
|
CAGR 10-Years
35%
|
See Also
What is Biohaven Pharmaceutical Holding Company Ltd's Accounts Payable?
Accounts Payable
15.6m
USD
Based on the financial report for Dec 31, 2023, Biohaven Pharmaceutical Holding Company Ltd's Accounts Payable amounts to 15.6m USD.
What is Biohaven Pharmaceutical Holding Company Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
77%
Over the last year, the Accounts Payable growth was 46%. The average annual Accounts Payable growth rates for Biohaven Pharmaceutical Holding Company Ltd have been 77% over the past three years .